Compare

Coloplast A/S/DKr COLO B

1D1W1M3M6MYTD1Y5YMAX

About Coloplast A/S

Coloplast A/S is a Danish company specializing in the development and manufacturing of medical devices and services. Its core business operates within the healthcare industry, focusing on products for ostomy care, continence care, wound and skin care, and urology. Founded in 1957, the company has a significant history of innovation in personalized healthcare products. Headquartered in Humlebæk, Denmark, Coloplast serves a global market, ensuring strong geographic diversification. The company is strategically positioned with strengths in customer-centric product development and a robust distribution network, enhancing its competitive advantage in the medical devices sector.
Ticker
DKr COLO B
Sector
Health
Primary listing
CSE
Employees
17,213
Headquarters
Humlebæk, Denmark
Website
www.coloplast.com

Coloplast A/S Metrics

BasicAdvanced
kr 109B
39.35
kr 12.26
0.55
kr 23.00
4.77%

Bulls say / Bears say

Core Chronic Care demand remains healthy: in the latest quarter, Continence Care grew 8% and Ostomy Care 5%, with double-digit US growth in both areas. This helps offset weakness elsewhere. (Coloplast)
Interventional Urology grew 7% in the quarter, led by US Men’s Health. FDA approval of the next-generation Titan Prime implant and the Uromedica acquisition give the business further growth drivers. (Coloplast)
Kerecis could become less of a drag if its larger inpatient business continues to grow and the outpatient market stabilises. Coloplast expects the wound-care unit to return to growth from January 2027; inpatient care represents about 70–80% of Kerecis sales and was largely unaffected by the reimbursement change. (Reuters)
US Medicare payment changes have disrupted Kerecis outpatient sales, leaving the unit with a 6% sales decline in Q3 and a 3 billion DKK goodwill write-down. Coloplast expects roughly flat Kerecis growth for the full year. (Reuters, Coloplast)
Profitability is under pressure: the Q3 EBIT margin fell to 26% from 28% a year earlier, with currency and Kerecis effects weighing on results. Constant-currency EBIT growth was only 5% despite 6% organic revenue growth. (Coloplast)
The shares may be vulnerable if earnings growth fails to catch up with their valuation. J.P. Morgan said Coloplast traded at a roughly 20% premium to medtech peers despite slower forecast earnings growth, and expected only 3% EPS growth in fiscal 2027. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.

Funds containing Coloplast A/S

AllEURUSD
Funds
Fund name
Fund size
DKr COLO B weighting
Xtrackers MSCI Nordic£XDN0
€1.1B0.60%
iShares STOXX Europe Mid 200€EXSD
€610M0.60%
iShares STOXX Europe 600 Health Care€EXV4
€709M0.55%
iShares MSCI Europe Health Care Sector€ESIH
€890M0.47%
iShares MSCI Europe Health Care Sector£ESIH
€890M0.47%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.